Daniel R Kuritzkes
Brigham and Women's Hospital Therapeutics CRS, Harvard Medical School · Massachusetts General Hospital · Brigham and Women's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
5
all conditions, ClinicalTrials.gov
NIH grants tied to them
20
6 more share only the name and are not shown
Trial papers
79
PubMed author-name match
Trials
Studies that name Daniel R Kuritzkes as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:00 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03705169 · Pharmacokinetics and Safety of SAR441236National Institute of Allergy and Infectious Diseases (NIAID) · terminated · HIV-1-infection · study chair
- Ph1/Ph2NCT02471430 · Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral TherapyMassachusetts General Hospital · completed · HIV Infection · principal investigator
- Ph2/Ph3NCT02369406 · Early Infant HIV Treatment in BotswanaHarvard School of Public Health (HSPH) · active not recruiting · HIV, Pediatric AIDS · principal investigator
- N/ANCT00709397 · HIV-1 Viral Dynamics in Subjects Initiating Raltegravir TherapyBrigham and Women's Hospital · terminated · HIV-1 Infection · principal investigator
- Ph1/Ph2NCT00031044 · Adding New Drugs for HIV Infected Patients Failing Current TherapyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · HIV Infections · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in BotswanaU01AI179561 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · fiscal years 2023 to 2026 · $1,112,870 awarded in 2026Same name and institution; not confirmed by an ID
- Boston HIV CTUUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2014 to 2026 · $5,028,996 awarded in 2026Same name and institution; not confirmed by an ID
- Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2013 to 2026 · $409,905 awarded in 2026Same name and institution; not confirmed by an ID
- HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapyR01AI157854 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2021 to 2025 · $791,766 awarded in 2025Same name and institution; not confirmed by an ID
- A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · fiscal years 2018 to 2024 · $361,377 awarded in 2024Same name and institution; not confirmed by an ID
- Viral Infection and Inflammation Workshop 2024R13AI186262 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2024 · $7,000 awarded in 2024Same name and institution; not confirmed by an ID
- A Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2015 to 2020 · $2,373,615 awarded in 2020Same name and institution; not confirmed by an ID
- Early Infant TreatmentU01AI114235 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · fiscal years 2014 to 2020 · $249,815 awarded in 2020Same name and institution; not confirmed by an ID
- Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2011 to 2018 · $60,609,395 awarded in 2018Same name and institution; not confirmed by an ID
- Antiretroviral drug resistance in KwaZulu NatalR01AI098558 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2013 to 2017 · $221,602 awarded in 2017Same name and institution; not confirmed by an ID
- HIV-1 Resistance to Chemokine Receptor AntagonistsR37AI055357 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2007 to 2016 · $444,500 awarded in 2016Same name and institution; not confirmed by an ID
- Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTUUM1AI069472 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2012 to 2014 · $455,841 awarded in 2014Same name and institution; not confirmed by an ID
- Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTUU01AI069472 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2007 to 2011 · $3,249,397 awarded in 2011Same name and institution; not confirmed by an ID
- HIV-1 Therapeutics and Drug ResistanceK24RR016482 · NCRR · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2001 to 2010 · $116,619 awarded in 2010Same name and institution; not confirmed by an ID
- V3 loop characterization by ultradeep sequencing during CCR5 antagonist therapyR21AI077469 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2009 to 2010 · $222,500 awarded in 2010Same name and institution; not confirmed by an ID
- Core--Molecular Virology and Molecular Biology FacilityP30AI060354 · NIAID · HARVARD MEDICAL SCHOOL · fiscal years 2005 to 2008 · $506,414 awarded in 2008Same name and institution; not confirmed by an ID
- A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTSM01RR002635 · NCRR · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2006 · $2,294 awarded in 2006Same name and institution; not confirmed by an ID
- AIDS CLINICAL TRIALS UNITU01AI027659 · NIAID · HARVARD MEDICAL SCHOOL · fiscal years 2003 to 2006 · $1,516,319 awarded in 2006Same name and institution; not confirmed by an ID
- Fitness of Enfuvirtide-(T-20)-Resistant HIV-1R01AI055357 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2003 to 2006 · $337,869 awarded in 2006Same name and institution; not confirmed by an ID
- HIV-1 resistance to nucleoside analoguesR01AI042567 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 1998 to 2004 · $374,340 awarded in 2004Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:00 UTC. The ranking covers the 200 most relevant of 79 PubMed records, and a shared surname and initials can bring in a namesake. All 79 on PubMed
- Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.N Engl J Med · 2003752 citationsRCR 17.2
- Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.N Engl J Med · 1995462 citationsRCR 13.0
- Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.N Engl J Med · 2004428 citationsRCR 10.3
- 320 citationsRCR 6.9
- Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.Ann Intern Med · 1995240 citationsRCR 7.0
- 221 citationsRCR 7.7
- Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.Ann Intern Med · 1997220 citationsRCR 6.1
- Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.J Infect Dis · 2007211 citationsRCR 5.3
- 178 citationsRCR 4.4
- 151 citationsRCR 4.2